Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.

This study reported that alopecia occurred in 2.5% of patients with mycosis fungoides or Sézary syndrome, with some cases resembling alopecia areata and others associated with specific skin lesions.